Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


How FDA Reads an Ad

This article was originally published in RPM Report

Executive Summary

Sponsors wondering what kind of feedback FDA will give on proposed TV ads can turn to the public record: enforcement letters issued by the agency. Here is the most recent example of FDA's objections to a commercial, in the agency's own words.

You may also be interested in...

The New Era in DTC: FDA Plans New Fees, Fines-and Creative Advice

The new FDA law marks a turning point in the relatively short history of direct-to-consumer broadcast ads. Sponsors have preserved the right to advertise, but will have to get used to following FDA's schedule-and taking FDA's advice.

The Tortoise, The Hare, And COVID Vaccines: The Hare Wins

Merck wasn’t as quick to the COVID vaccine race as some others, but it believed that its use of ‘proven platforms’ would win out in the end. Not anymore.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts